MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the first and only FDA-approved, non-incisional permanent birth control method available, announced today that new independent study data released at the 35th Annual Meeting of the American Association of Gynecologic Laparoscopists (AAGL) shows the Essure system eliminates risks associated with traditional surgical sterilization for many women not eligible for permanent birth control.
